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Introduction
HIV persistence in latently infected, resting CD4+ T cells is broadly recognized as a barrier to eradicating 
HIV (1, 2). To eliminate the latent reservoir, infected cells must be recognized as harboring virus and then 
effectively destroyed and cleared. Latency disruption is under intense investigation, and several strategies 
are being evaluated (3–6). Recent therapeutic approaches have focused on the use of  latency-reversing 
agents (LRAs) to induce viral transcription, initiate viral translation, and subsequently elicit death through 
viral cytopathic effects or immune-mediated cell killing (“shock and kill”). A class of  small molecules 
known as histone deacetylase inhibitors (HDACis) has been broadly examined as LRAs, and clinical stud-
ies have shown that single and multiple administration results in induced viral RNA transcription in CD4+ 
T cells from antiretroviral therapy–suppressed (ART-suppressed) HIV+ subjects (7–11). However, direct 
quantitation of  cell-associated viral protein following clinical administration of  HDACis has not been pos-
sible. Other agents, such as bromodomain inhibitors and protein kinase C (PKC) agonists, have also been 
shown to induce viral transcription in vitro and in preclinical models and are under further evaluation as 
potential clinical HIV “shock” agents (6, 12–16). Worth noting, the induction of  viral protein expression 
is a prerequisite for several investigational immune-mediated “kill” strategies (3–5). Broadly neutralizing 
antibodies are already being used in clinical trials, and other strategies involving the use of  other forms 
of  antibodies that target viral protein are currently being developed, highlighting the need for approaches 
that can demonstrate low-level detection of  viral antigens and report on the efficacy of  such therapeutic 
approaches (5, 17, 18).
The exploration of  cure strategies targeting the latent HIV reservoir highlights a need for new assays 
and research tools to quantify viral burden in tissue and various body fluids.
Promising therapeutic approaches for eradicating HIV include transcriptional activation of provirus 
from latently infected cells using latency-reversing agents (LRAs) and immune-mediated clearance 
to purge reservoirs. Accurate detection of cells capable of producing viral antigens and virions, 
and the measurement of clearance of infected cells, is essential to assessing therapeutic efficacy. 
Here, we apply enhanced methodology extending the sensitivity limits for the rapid detection of 
subfemtomolar HIV gag p24 capsid protein in CD4+ T cells from ART-suppressed HIV+ individuals, 
and we show viral protein induction following treatment with LRAs. Importantly, we demonstrate 
that clinical administration of histone deacetylase inhibitors (HDACis; vorinostat and panobinostat) 
induced HIV gag p24, and ex vivo stimulation produced sufficient viral antigen to elicit immune-
mediated cell killing using anti-gp120/CD3 bispecific antibody. These findings extend beyond 
classical nucleic acid endpoints, which are confounded by the predominance of mutated, defective 
proviruses and, of paramount importance, enable assessment of cells making HIV protein that can 
now be targeted by immunological approaches.
The rare incidence of  latently infected cells for which robust phenotypic markers are still needed pres-
ents a significant challenge for identifying these cells and measuring changes in viral expression (3, 19, 20). 
In addition, latency reversal may induce proviral transcription in only a fraction of  this population, and the 
observed increases in cellular HIV-1 RNA may represent defective proviruses and could also result from 
alternative splicing or read-through transcripts, which may not give rise to efficient splicing, translation, and 
protein expression (19–22). Quantifying virus production has been difficult, and traditional cell culture–
based assays, such as viral outgrowth assays (VOA), which measure HIV gag p24 antigen in culture medium 
after expansion in culture for 2–3 weeks, require large sample volumes and have limited throughput and 
clinical application (23, 24). TILDA, as an example of  many cell-associated HIV RNA assays described, 
may offer some advantages to quantitative VOA (qVOA) such as increased throughput and decreased sample 
requirements, but still only measures RNA transcripts (25). An alternative approach that directly measures 
protein production and also affords increased sensitivity as a component of  an existing ex vivo assay for 
measuring HIV reservoir and/or can be leveraged to assess protein levels needed to induce viral cytopath-
icity or promote immune-mediated clearance is an important advancement for HIV cure research (26–28). 
Toward this goal, we report and apply enhanced methodology for rapid and sensitive detection of  HIV gag 
p24 protein in latently infected CD4+ T cells from ART-suppressed HIV+ individuals and demonstrate that 
latency reversal of  HIV can produce sufficient viral antigen to enable immune-targeted clearance.
Results
Direct measurement of  HIV gag p24 in ART-suppressed HIV+ CD4+ T cells. Recent studies have reported the use 
of  a digital immunoassay to measure HIV gag p24 protein from serum or plasma of  acutely infected HIV+ 
individuals or cultured media of  HIV-infected CD4+ T cells (29–31). Despite these advances, commercial 
methods encounter matrix issues and lack the same degree of  sensitivity in quantifying cell-associated 
viral p24 protein from aviremic HIV+ individuals. To overcome this limitation, we optimized the digital 
immunoassay protocol, detailed in Methods, for the rapid and sensitive detection of  HIV gag p24 protein 
in latently infected CD4+ T cell lysates prepared from ART-suppressed HIV+ individuals and applied this 
approach to assess proviral reactivation and immune-mediated cell kill. Robust linearity in detecting p24 in 
CD4+ T cell lysates from aviremic HIV+ individuals was demonstrated with an analytical limit of  detection 
(LOD) of  5 fg/ml (Figure 1A), corresponding to 125,000 p24 copies/ml or 18,000 copies/144 μl assay 
input and, thus, about 9 viruses/144 μl input (29, 30). The optimized methods extended the sensitivity 
LODs for HIV p24 in cell lysates (Figure 1B). Additional studies in the HIV-1–infected MOLTIIIB cell line 
also suggested HIV gag protein quantification is feasible in 0.125 cells/ml lysate (~2% cell/144 μl) in this 
cell model (Supplemental Figure 1A; supplemental material available online with this article; https://doi.
org/10.1172/jci.insight.92901DS1),
To demonstrate assay specificity and breadth, we first evaluated p24 levels in BSA/PBS buffer alone 
and CD4+ T cells isolated from uninfected or ART-suppressed HIV+ donors and treated ex vivo with either 
PMA/Ionomycin or the HDACi vorinostat (VOR). Detectable p24 levels were observed only in HIV+ cell 
lysates (Figure 1C). Additionally, magnetic bead-based immunodepletion studies were performed using 
either p24 ELISA antibodies or mouse IgG incubated with CD4+ T cell lysates from HIV+ viremic donors. 
HIV gag p24 was absent in the flow-through (FT) of  p24 antibody–depleted samples but measurable in the 
IgG control FT, demonstrating specificity of  the assay for HIV gag protein (Supplemental Figure 1B). To 
further assess whether the assay also recognized unprocessed gag polyprotein, recombinant proteins p55 
and p24 were diluted 2-fold from 20–0.3 fM in 3% BSA/PBS buffer and measured simultaneously. Linear 
dilution and low fg/ml detection of  recombinant p55 was observed, suggesting recombinant HIV gag p55 
polyprotein is also measurable in vitro (Supplemental Figure 1C). It is unclear, however, how efficiently the 
p24 antibody recognizes gag p55 in vivo. Assay breadth was demonstrated by evaluating viral lysates from 
18 genetically diverse clinical isolates, including 8 HIV-1 subtypes spanning groups M and O, and 1 HIV-2 
isolate. As shown in Figure 1D, viral HIV gag protein was detected in all 18 clinical isolates, and protein 
values correlated significantly with RNA copies/μl (r = 0.837; P < 0.001; data not shown).
Latency-reversing agents induce viral p24 expression. Viral protein production is critically important to inves-
tigational immunotherapies (5, 17, 18, 32, 33), and thus, it is equally important to assess viral protein 
production following latency reversal and, subsequently, to determine if  the level of  viral protein induction 
on a reactivated cell is sufficient to enable immune-mediated clearance. Classical measures of  the HIV res-
ervoir leverage nucleic acid readouts to estimate the burden of  disease or viral transcription, but they often 
overestimate reservoir size due to the presence of  defective proviruses. Techniques that quantify the fre-
quency or percentage of  cells that become transcriptionally active following viral reactivation have recently 
been developed, including the Tat/Rev-induced msRNA limiting dilution assay (TILDA); however, assays 
like TILDA do not quantify translationally competent proviruses. Toward the initial goal of  detecting viral 
protein upon latent cell reactivation, we assessed the relationship between HIV-1 gag protein induction and 
inducible reservoir size, as measured by TILDA, in 11 ART-suppressed subjects following 48-hour PMA/
Ionomycin stimulation. TILDA measurements allowed the segregation of  subjects into 3 categories of  
small, moderate, and large inducible reservoirs (Figure 2A). The majority of  subjects displayed inducible 
p24 levels that trended positively with the TILDA readout; however, a statistically significant correlation 
between TILDA and p24 was lacking (r = 0.54, P < 0.1; Figure 2B). Notably, a significant correlation was 
observed between p24 measured in cell lysates and culture medium (r = 0.83, P = 0.005; Figure 2C), and 
extended studies are underway to assess virus-associated p24 in the culture medium versus contribution, if  
any, from cellular leakage. Next, we evaluated HIV reactivation in cells treated ex vivo with either 10 nM 
ingenol-3-angelate, 5 μM bromosporine, or 750 nM VOR and observed comparable trends between TILDA 
and p24 following 48-hour stimulation of  CD4+ T cells from ART-suppressed HIV+ subjects (Figure 2, 
Figure 1. Ultrasensitive detection of HIV gag p24. (A) Linear dilution and low fg/ml detection of recombinant p24 spiked into CD4+ T cell lysates from 
uninfected donors, representative of n = 4. AEB, average enzyme per bead. (B) Representative data of n = 3 of robust p24 quantitation in cell lysates from 
ART-suppressed HIV+ CD4 T cells using new method versus historical (29, 30). (C) Measurable p24 in cell lysate and culture medium from HIV-infected CD4+ 
cells stimulated with PMA/ionomycin but not in uninfected CD4 cells stimulated either with PMA/ionomycin or SAHA, or in BSA/PBS buffer, n = 1. Dashed 
line represents analytical LOD, 5 fg/ml. (D) Detection of p24 in viral lysates from 18 clinically diverse HIV-1/2 subtypes.
D and E). Measurable induction was also observed at shorter incubation periods (6–24 hours; data not 
shown). Importantly, we demonstrate that HDACis and other LRAs can elicit both viral RNA and protein 
expression ex vivo.
VOR and panobinostat induce HIV gag p24 following clinical HDACi administration. HDACis are the most 
studied latency-reversing agents and have shown induction of  cell-associated HIV RNA in vivo using 
single or multiple dosing paradigms (7–11, 34); however, no study to date, to our knowledge, has demon-
strated the direct induction of  viral protein after clinical administration of  HDACis. To determine if  in 
vivo dosing of  HDACis can induce viral protein expression, we examined changes in cell-associated p24 
from peripherally isolated CD4+ T cells following clinical administration of  2 HDACis, either VOR or 
panobinostat. A limited number of  available samples were obtained from previously published or recent-
ly completed clinical trials (9, 10, 34). Briefly, aviremic HIV+ individuals received either VOR (400 mg) at 
72-hour intervals or panobinostat (20 mg) 3 times per week every other week for 8 weeks while maintain-
ing combination ART (9, 10, 34). We quantified changes in p24 from baseline following administration
of  1, 2, or 10 doses of  VOR (9, 34), as well as multiple doses (6 – 10) of  panobinostat (Supplemental
Table 1), for subjects in whom remaining samples were available for p24 assessment. In the VOR study,
PBMCs were collected from HIV+ subjects by leukapheresis 3–6 hours after VOR, and total CD4+ T cells
were subsequently isolated and cultured for 48 hours with 1 μM raltegravir to prevent further rounds
of  infection. Peripheral blood cells were obtained by venipuncture on panobinostat-treated subjects at
baseline and 8 hours after dose. Similarly, CD4+ T cells were isolated and cultured with 1 μM raltegravir
Figure 2. Comparison of TILDA and p24 protein expression following latency reversal in ART-suppressed CD4+ T cells. (A) Comparison of cell-associated p24 
and inducible reservoir sizes, as measured by TILDA, from 11 ART-suppressed HIV+ subjects, n = 1 per patient. IUPM represents the number of tat/rev msRNA–
expressing cells per million, and IUPM values are ranked left to right. (B) Correlation study of TILDA and cell-associated p24; r = 0.54, P = 0.1, Spearman correla-
tion test. (C) Significant correlation observed between p24 in cell lysates and tissue culture medium (TCM); r = 0.83, P = 0.005, Spearman correlation method. 
(D and E) Quantitation of HIV reactivation by TILDA (D) and p24 digital ELISA (E) following 48-hr ex vivo stimulation with latency-reversing agents in CD4+ T 
cells from ART-suppressed HIV+ subjects. n = 3 subjects per condition. PMA, PMA/ionomycin; ING, ingenol-3-angelate; BRD, bromosporine; VOR, vorinostat.
for 48 hours. Cells were cultured to allow sufficient time for p24 translation to occur, since collection 
was performed within a few hours of  drug administration to enable the primary clinical study endpoint 
measurements of  RNA quantitation. Applying this approach, 3 of  6 VOR-treated subjects showed mea-
surable increases in p24 protein above baseline, primarily after the second dose, and dilution of  donor 
V-1 sample demonstrated linear detection of  p24 within the analytical range of  the assay (Figure 3A and
Supplemental Figure 2). An additional sample was available for a patient receiving 10 doses of  VOR and
showed p24 induction above baseline in both total and resting memory CD4+ T cell populations (Figure
3B). Both VOR dosing paradigms results in increased cell-associated HIV-1 gag RNA in the subjects
studied (Figure 3, C and E; refs. 9 and 34). For the participant receiving 10 doses of  VOR, p24 was
assessed immediately after thawing cells and demonstrates the ability to also detect protein without time
in culture, although it is unknown whether or not dependencies exist between the numbers of  clinically
administered doses, the time of  sample collection, and the detection of  p24. In the panobinostat study,
Figure 3. Clinical administration of HDACis induces HIV protein expression in ART-suppressed 
subject CD4+ T cells. (A–C) In vivo vorinostat administration induces p24 expression in CD4+ T 
cells following 1, 2 (A), or 10 (B) doses of vorinostat administered clinically every 72 hrs (refs. 7, 
9; see ref. 34 for cell-associated HIV RNA levels corresponding to single and paired VOR dosing), 
and (C) for 10-dose VOR. (D) Clinical administration of panobinostat resulted in statistically 
significant increase in p24 above baseline, ***P < 0.001 student’s t test (see ref. 10 for RNA 
data; open circle represents 1 fg/ml p24, a value below analytical limit of detection [LOD]). (E) 
Comparison of post-/pre-HDACi ratios of mean cell-associated (ca) HIV gag RNA copies/ml and 
gag protein fg/ml following clinical administration of vorinostat (open squares) or panobinostat 
(closed circles), with statistical significance determined using linear regression (P < 0.01). n = 11. 
Note, subject V-1 was the only participant who was not observed to have an induction of ca-RNA 
(40) after VOR administration, although an increase of cell-associated p24 was detected. If this 
data point was excluded (asterisk), the correlation between induction of cell-associated p24 and
ca-HIV RNA would be even more significant.
p24 measurements were also made on available samples from 5 of  15 participants from the Rasmussen 
et al. study (10), as shown in Supplemental Table 1. Briefly, 4 participants had matched baseline and 
post-panobinostat samples, with the panobinostat samples collected the same day as drug administration 
(participants 6, 8, 17, and 18; Supplemental Table 1). To rule out selection bias, we have included data 
comparing the fold change in cell-associated HIV RNA at the relevant time points in the panobinostat 
study for the 5 individuals contributing samples for the present study versus the remaining 10 study par-
ticipants (Supplemental Figure 3). Four of  4 subjects showed increased p24 relative to baseline following 
either the seventh panobinostat dose (participants 8, 17, 18) or ninth dose (participant 6; Figure 3D), 
with the increase being statistically significant (P < 0.001). Participant 5 was examined 5 days after the 
sixth dose of  panobinostat (i.e., during the rest period; Supplemental Table 1) and showed no detectable 
change relative to baseline (Figure 3D). Of  note, this patient displayed very low levels of  cell-associated 
RNA during panobinostat treatment and, like only 1 of  15 participants in the original study, plasma HIV 
RNA from this individual remained continuously undetectable throughout the clinical study (10). Thus, 
it remains unclear if  this represents a return to baseline 5 days after drug administration or if  it represents 
very low p24 levels. Comparison of post-/pre-HDACi ratios of  mean cell-associated HIV gag RNA and 
protein following clinical administration of  HDACis showed statistical significant correlations (Figure 
3E, P < 0.01). Collectively, these data demonstrate that clinical administration of  HDACis increase viral 
RNA transcription and viral protein expression.
Figure 4. Immune-mediated clearance of HIV+ CD4+ T cells following HIV reactivation and redirected CD8+ T cell killing. (A) Schematic of 
immune-mediated targeting of HIV+ CD4+ T cells by autologous CD8+ T cells using gp120/CD3 bispecific antibodies. (B and C) Quantitation of p24 in 
cell lysates following 72-hr ex vivo HIV reactivation of ART-suppressed CD4+ T cells with either PMA/ionomycin, n = 3 subjects (B), or vorinostat, n 
= 4 subjects (C). p24 concentrations are reduced significantly in the presence of gp120/CD3 (ENV) but not RSV/CD3 (RSV) bispecific antibodies. (D) 
Ratio HIV gag protein changes following latency reactivation with either VOR or PMA/ionomycin relative to unstimulated (LRA/DMSO) or in the 
presence of either HIV ENV (LRA/LRA+ENV BsAb) or RSV (LRA/LRA+RSV BsAb) bispecific antibodies. Input numbers are shown for PMA/iono-
mycin- or VOR-treated cells. Ratios were excluded when 1 comparator was below analytical LOD. Significance was determined using ANOVA. **P < 
0.01. Error bars indicate mean ± SEM.
Latency reversal induces sufficient viral protein to enable immune-based clearance. As highlighted above, sev-
eral current immunological strategies are aimed at engaging the immune system to clear HIV+-expressing 
cells (5, 17, 18, 32, 33). We hypothesized that in vivo and ex vivo treatment with latency-reversing agents 
could result in sufficient viral protein expression to enable redirected CD8+ cell killing and that chang-
es in viral levels could be assessed directly by measuring a reduction in HIV gag p24. To explore this 
hypothesis, autologous CD4+ and CD8+ T cells were isolated from ART-suppressed HIV+ subjects and 
coincubated at endogenous levels with either a low concentration of  PMA/ionomycin (10 ng/ml PMA 
+ 0.1 μg/ml ionomycin) or 380 nM VOR for 72 hours in the presence or absence of  gp120/CD3 or RSV/
CD3 bispecific antibodies (BsAbs; Figure 4A). As shown in Figure 4, statistically significant increases
in p24 protein were observed over DMSO controls following ex vivo stimulation of  CD4+ T cells with
either latency-reversing agent (P < 0.01). The addition of  gp120/CD3 BsAbs to the culture of  HIV+
reactivated cells resulted in reduced p24 protein, comparable with DMSO levels, whereas the addition
of  the control RSV/CD3 BsAb had no appreciable effect and showed comparable p24 levels with PMA/
ionomycin (Figure 4B) or VOR (Figure 4C) treatment alone. We also found that shorter incubations of
latency-reversing agents (<24 hrs) in isolated cells from ART-suppressed HIV+ individuals produced suf-
ficient protein for immune-mediated clearance (data not shown). Interestingly, the extent of  p24 protein
reduction in the presence of  HIV+ envelope (ENV) BsAb and latency reversal is ~1.5-fold that of  induced 
protein following latency reversal alone and significantly greater than respiratory syncytial virus (RSV)
BsAb controls (P < 0.01), thereby suggesting efficient clearance of  reactivated latent cells, as well as cells
persistently expressing HIV antigen (Figure 4D). CD4+ T cell viability remained similar across treatment
conditions (Supplemental Figure 4). These proof-of-concept studies illustrate HDACis, as well as other
latency-reversing agents, can elicit viral protein production to facilitate redirected cell killing and support
immune clearance approaches under evaluation (5, 17, 18, 35–39).
Discussion
The investment in HIV cure research and the ability to monitor the effectiveness of  therapeutic interven-
tions will depend largely on accurate and sensitive quantitation of  viral burden in different tissues and 
body fluids. New ELISA technologies support increased detection of  HIV gag p24 in plasma, serum, and 
cultured cell medium; however, these methods show decreased sensitivity in cell lysates due to matrix inter-
ference and in plasma and serum of  chronically infected HIV+ subjects due to immune complex formation 
after seroconversion (29, 30). Here, we report optimized methods that enable sensitive and rapid detection 
of  subfemtomolar cell–associated HIV gag p24 protein in HIV-infected CD4+ T cells from ART-suppressed 
individuals. Quantifying very small amounts of  cell-associated viral antigen produced by low numbers of  
cells from aviremic/low-reservoir HIV+ individuals is an important advancement, as viral protein expres-
sion is believed to contribute to tissue inflammation and persistent immune activation, and induction is 
a prerequisite for several investigational immune-mediated “kill” strategies (3–5, 40). The assay can be 
completed in approximately 1 hour, typically requires 1–2 million peripheral CD4+ T cells from ART-sup-
pressed HIV+ individuals, and can be applied to quantify viral protein in cell lysates or culture medium.
It is well established that the majority of  HIV proviruses harbor defective genomes and, thus, fail to pro-
duce replication-competent virus (20). Traditional assays aimed at reservoir characterization measure HIV 
DNA or RNA and are sensitive and scalable but have limitations in distinguishing defective from translation- 
or replication-competent proviruses. This inherently leads to an overestimation of  the size of  the reservoir 
(20). In our study, we compared the relationship between HIV-1 gag protein production and inducible reser-
voir size, as measured by tat/rev multiply spliced RNA (msRNA) (TILDA). Although a positive trend was 
observed, this did not reach statistical significance, which may be attributable, in part, to poor PCR probe 
recognition due to mismatches in HIV proviral sequences or to the inability of  inducible RNA to make pro-
tein. Conversely, the presence of  transcriptionally competent “defective” proviruses capable of  producing 
aberrant gag protein that may be poorly recognized by the p24 antibody is also a possible explanation (40). 
Worth noting, significant correlations were observed between HDACi-induced cell-associated RNA and pro-
tein from blood CD4+ T cells in subjects treated clinically with HDAC inhibitors, and further work is ongoing 
to inform on the correlations between p24 immunoassay and other viral endpoints, including qVOA. Overall, 
assessment of  HIV gag protein provides a tool for measuring protein production following latency reversal 
or protein levels needed to induce viral cytopathicity or promote immune-mediated clearance; it also affords 
increased sensitivity as a component of  an existing ex vivo assay for measuring HIV reservoir (26–28).
In this study, we show the first direct evidence to our knowledge that clinical administration of  HDA-
Cis results in measurable increases in HIV-1 gag p24 protein in CD4+ T cells. Additionally, we show ex 
vivo HDACi treatment of  autologous CD4+ and CD8+ T cells from ART-suppressed HIV+ individuals can 
induce reactivation of  HIV and produce sufficient viral antigen to enable redirected immune cell killing, 
mediated by gp120/CD3 BsAbs. These observations have implications for evaluating HIV-1 eradication 
strategies, as they highlight application of  an ultrasensitive, rapid tool for monitoring the rarer population 
of  translation-competent virus that must be effectively reactivated and cleared. Future studies geared at 
assessing other viral antigens, sequencing viral genomes, and conducting viral outgrowth studies to assess 
relationships between defective proviruses producing RNA-competent protein, replication-competent virus, 
and HIV protein production will be informative to understanding how the generation of  viral antigens also 
contributes to persistent immune activation. Furthermore, in light of  the clinical studies using broadly neu-
tralizing antibodies and antibody-based approaches to engage the immune system, this approach becomes 
increasingly important for assessing the reduction of  HIV-expressing cells and the effectiveness of  “shock 
and kill” strategies in preclinical or clinical settings.
Methods
Reagents. PMA, ionomycin, ingenol-3-angelate, and bromosporine were purchased from Sigma-Aldrich. 
Raltegravir and VOR were synthesized at Merck. Recombinant HIV gag p24 protein was obtained from 
US Biological.
Isolation of  T cells. Leukapheresis was performed on VOR subjects over a period spanning 3–6 hours 
after dose, and venipuncture was performed on panobinostat subjects at 8 hours after dose. PBMCs were 
isolated either from leukopaks or from whole blood via Ficoll-gradient. Resting CD4+ T cells, total CD4+ 
T cells, and total CD3+ T cells were isolated from PBMCs using Stemcell Technologies kits, as previously 
described (7, 9, 10, 25).
Ex vivo HIV reactivation. Enriched CD4+ T cells (1 × 106 to 5 × 106 cells/ml) were cultured in complete 
RPMI 1640 media (cRPMI) containing 10% FBS, 2 mM glutamine, and the antibiotics penicillin and strep-
tomycin. Cells were treated ex vivo for indicated times with either 0.1% DMSO, 100 ng/ml PMA/1 μg/ml 
ionomycin, 10 ng/ml PMA/0.1 μg/ml ionomycin, 10 nM ingenol-3-angelate, 5 μM bromosporine, 750 nM 
VOR, or 380 nM VOR. For TILDA studies, cells were collected and put through a 35-μm cell strainer (BD 
Falcon; Thermo Fisher Scientific) to remove cell clumps, and cell yield following titration was greater than 
90%. For p24 studies, cells and culture medium were recovered after the treatment period by centrifugation at 
1500 g for 5 minutes at room temperature. Cell density and viability were determined with a Vi-cell XR instru-
ment (Beckman Coulter). Samples were processed for p24 digital ELISA and TILDA as described below.
HIV p24 digital immunoassay. The fully automated Quanterix HD-1 analyzer for single molecule detec-
tion has been reported previously (29–31). In this study, cell lysates were prepared by adding a final concen-
tration of  1% Triton X-100/PBS to 2 × 106 cells. For culture medium supernatants, Triton X-100 was added 
to a final concentration of  1% (10% volume of  10% Triton x-100 prepared in PBS). Samples were stored 
frozen at –80°C for more than 1 hour or until analysis. Upon thaw, cell lysates were diluted 2- to 5-fold with 
dilution buffer (50% of  blocker casein in PBS [Thermo Fisher Scientific, catalog 37528] and 50% of  FBS 
(Thermo Fisher Scientific, catalog 10438018]). For culture medium supernatants, samples were diluted 
with an equal volume of  dilution buffer and frozen at –80°C until analysis or minimally > 1 hour. Samples 
were then centrifuged for 5 minutes at 10,000 g at room temperature to remove insoluble material prior to 
p24 measurement on the Quanterix analyzer. All other assay reagents and assay reaction conditions fol-
lowed the manufacturer’s p24 kit protocol (29, 30) (Quanterix). p24 concentration was calculated based on 
a p24 calibration curve with 4-parameter curve fitting.
p24 assay specificity. p24 was quantified in BSA/PBS buffer alone or in lysates from uninfected or HIV+ 
CD4+ T cells in the presence and absence of  either PMA/ionomycin or VOR. Additionally, HIV+ CD4+ T 
cells from viremic donors were lysed (1 million cells/ml) in 1% Triton x-100/PBS and divided into 4 aliquots 
(1 ml each) in eppendorf  tubes. Simoa capture antibody beads (100 μl), or beads with detection antibody or 
normal mouse IgG (biotin-labeled simoa detection antibody or mouse IgG) were incubated with Dynabeads 
with streptavidin (M-280) at 4°C for 2 hours. Unbound antibody was washed away, and magnets were added 
into each tube, mixed, and incubated at 4°C overnight. The supernatant FT after IP was collected by mag-
net, and p24 in FT was measured in Simoa (Quanterix). BSA/PBS (3%) was negative in the assay, and mock 
IP lysate was used as positive sample. Immunodepletion results are shown in Supplemental Figure 1B.
In a separate study, MoltIIIB cell line (AIDS Research Program) with 100% integrated HIV was 
resuspended initially at 1 × 106 cells/ml culture medium and further diluted to 100 cells/ml. 40 μl (4 cells) 
was added to 960 μl of  1% Triton x-100 in PBS to become 4 cells/ml lysate. Lysate was further diluted in 
3% BSA/PBS from 4–0.125 cells/ml, and p24 was quantified using digital ELISA. Results are shown in 
Supplemental Figure 1A.
To assess whether the assay also recognized unprocessed Gag polyprotein, recombinant protein p55 
(Invitrogen, catalog RP4920) and p24 (US Biological, catalog H6003-25) were measured simultaneously 
in Quanterix p24 assay. Both proteins were diluted with 3% BSA/PBS starting at 20, 10, 5, 2.5, 1.25, 0.62, 
0.3, and 0 fM. Both samples were measured in p24 digital ELISA, and the data were graphed based on the 
spiking in p24 or p55 concentration (fM) and the signal average enzyme per bead (AEB). Results are shown 
in Supplemental Figure 1C.
HIV virus cultures. HIV isolates representing HIV-1 group M (subtype A, B, C, D, AE, G) and O and 
HIV-2 were obtained from the NIH AIDS Reference and Reagent Repository (Germantown, Maryland, 
USA) or isolated from CD8-depleted PBMCs by coculture with PHA-activated T cells from healthy donors. 
Virus isolates evaluated included 93RW034, JrFl, Bal, QZ4589, ASM57, 92TH594, 93BR029, BRH84155, 
BRH95436, ZA/97/003, 93MW959, 92UG024, THA/92/006, RU570, JV1083, 301342, 301340, and 
BCF03. Working stocks were amplified by infecting PHA-activated PBMCs or MT-4 cells stably expressing 
the CCR5 coreceptor and GFP virus. Viral isolates were harvested from the culture supernatant without 
additional purification. Diluted virus was inactivated with addition of  final 1% Triton x-100 in PBS and 
incubated at room temperature for 30 minutes and then frozen at –80°C until analysis. The viral lysate was 
diluted at 1:100, 1:1,000, 1:10,000, and 1:100,000 with 3% BSA/PBS before assay.
TILDA. TILDA analysis was performed as previously described (25) with modifications in quantitative 
PCR (qPCR) in which TaqMan Fast Advanced Master Mix instead of  LightCycler buffer was used and 
performed on a Quantstudio 12K flex instrument (Thermo Fisher Scientific).
Measurement of  p24 from clinical samples. Cryopreserved cells were thawed, and CD4+ T cells were isolated 
as described above. 2 × 106/ml CD4+ T cells per sample were cultured in the presence of  1 μM raltegravir 
for 48 hours in cRPMI media and then harvested and prepared for p24 quantification, as described above.
BsAbs and ex vivo shock and kill. Antibodies with dual specificity for HIV gp120 and CD3 were generated 
using published sequences. Antibodies containing a RSV-specific antibody (Synagis) arm and anti-CD3 
were also constructed and used as nonspecific control. CD3-enriched cells from HIV -infected ART-sup-
pressed donors were prepared as described above and cultured in cRPMI. Cells were seeded at a density of  
2 × 106 cells/ml and were incubated with either 0.1% DMSO, 10 ng/ml PMA and 0.1 μg/ml ionomycin, 
or 380 nM VOR in the presence or absence of  100 ng/ml BsAbs. Raltegravir was added at a final concen-
tration of  1 μM to prevent secondary rounds of  replication. Following a 72-hour incubation period, cell 
lysates were prepared and p24 was quantified, as described above.
Statistics. HIV gag protein concentration was calculated based on a calibration curve with linear regres-
sion 4-parameter curve fitting. A Spearman correlation test was used for analysis of  p24 in cell lysates ver-
sus culture medium as well as comparison with TILDA, and P < 0.05 was considered significant. ANOVA 
or two-parameter student’s t tests were used for statistical significance for all other statistical tests, and the 
method used is noted in the figure legends.
Study approval. HIV-infected subjects receiving stable, standard-of-care ART with plasma HIV-1 RNA 
fewer than 50 copies per ml and a CD4 count of  more than 300 μl-1 for at least 6 months were enrolled in 
the VOR clinical studies following informed consent (7, 9, 34); HIV-infected adults receiving ART with 
virological suppression (<50 copies per ml, at least 2 measurements per year) for at least 2 years and CD4 
counts above 500 cells per μl were enrolled in the panobinostat study following informed consent (10). 
VOR studies were approved by the UNC institutional biomedical review board and the FDA (7, 9, 34); 
panobinostat clinical study was conducted at Aarhus University Hospital, Denmark, and approved by the 
ethics committee in accordance with the principles of  the Declaration of  Helsinki (10). For ex vivo studies, 
additional samples were obtained from HIV+ donors with suppressed viremia (<50 copies per ml) from 
Philadelphia Fight and Sanguine Biosciences under IRB approval and patient informed consent.
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